Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
2014 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
Lehmann-Horn, K.; Kinzel, S.; Feldmann, L.; Radelfahr, F.; Hemmer, B.; Traffehn, S. & Bernard, C. C. A. et al. (2014)
Annals of Clinical and Translational Neurology, 1(7) pp. 490-496. DOI: https://doi.org/10.1002/acn3.71
Documents & Media
Details
- Authors
- Lehmann-Horn, Klaus; Kinzel, Silke; Feldmann, Linda; Radelfahr, Florentine; Hemmer, Bernhard; Traffehn, Sarah; Bernard, Claude C. A.; Stadelmann, Christine ; Brueck, Wolfgang; Weber, Martin S.
- Abstract
- Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.
- Issue Date
- 2014
- Status
- published
- Publisher
- Wiley-blackwell
- Journal
- Annals of Clinical and Translational Neurology
- ISSN
- 2328-9503
